Pituitary response profile following metoclopramide administration in women with different forms of hyperprolactinemia

References

• Kasum M, Pavičić-Baldani D, Stanić P, et al Importance of macroprolactinemia in hyperprolactinemia. Eur J Obstet Gynecol Reprod Biol 2014;183:28–32
   PubMed Web of Science ®Google Scholar
• Leaños-Miranda A, Ramírez-Valenzuela KL, Campos-Galicia I, et al Frequency of macroprolactinemia in hyperprolactinemic women presenting with menstrual irregularities, galactorrhea, and/or infertility: etiology and clinical manifestations. Int J Endocrinol 2013;478282. doi:10.1155/2013/478282
   PubMed Web of Science ®Google Scholar
• Gibney J, Smith TP, McKenna TJ. Clinical relevance of macroprolactin. Clin Endocrinol (Oxf) 2005;62:633–43
   PubMed Web of Science ®Google Scholar
• Olukoga AO. Macroprolactinemia is clinically important. J Clin Endocrinol Metab 2002;87:4833–4
   PubMed Web of Science ®Google Scholar
• Fahie-Wilson M, Smith TP. Determination of prolactin: the macroprolactin problem. Best Pract Res Clin Endocrinol Metab 2013;27:725–42
   PubMed Web of Science ®Google Scholar
• Leite V, Cosby H, Sobrinho LG, et al Characterization of big, big prolactin in patients with hyperprolactinaemia. Clin Endocrinol (Oxf) 1992;37:365–72
   PubMed Web of Science ®Google Scholar
• Hattori N, Ikekubo K, Ishihara T, et al A normal ovulatory woman with hyperprolactinemia: presence of antiprolactin autoantibody and the regulation of prolactin secretion. Acta Endocrinol 1992;126:497–500
   PubMedGoogle Scholar
• Hattori N, Ikekubo K, Nakaya Y, et al Immunoglobulin G subclasses and prolactin (PRL) isoforms in macroprolactinemia due to anti-PRL autoantibodies. J Clin Endocrinol Metabolism 2005;90:3036–44
   PubMed Web of Science ®Google Scholar
• Hattori N, Nakayama Y, Kitagawa K, et al Anti-prolactin (PRL) autoantibody-binding sites (epitopes) on PRL molecule in macroprolactinemia. J Endocrinol 2006;190:287–93
   PubMed Web of Science ®Google Scholar
• Coudevylle N, Rokas D, Sakarellos-Daitsiotis M, et al Phosphorylated and nonphosphorylated epitopes of the La/SSB autoantigen: comparison of their antigenic and conformational characteristics. Biopolymers 2006;84:368–82
   PubMed Web of Science ®Google Scholar
• Alhquist JAO, Fahie-Wilson M. On the origin and distribution of macroprolactin. 19th Meeting of the British Endocrine Societies; 2000; Birmingham
   Google Scholar
• Vallette-Kasic S, Morange-Ramos I, Selim A, et al Macroprolactinemia revisited: a study on 106 patients. J Clin Endocrinol Metab 2002;87:581–8
   PubMed Web of Science ®Google Scholar
• Whittaker PG, Wicox T, Lind T. Maintained fertility in a patient with hyperprolactinemia due to big, big prolactin. J Clin Endocrinol Metab 1981;53:863–6
   PubMed Web of Science ®Google Scholar
• Anderson AN, Pedersen H, Djursing H, et al Bioactivity of prolactin in a woman with an excess of large molecular size prolactin, persistent hyperprolactinemia and spontaneous conception. Fertil Steril 1982;38:625–8
   PubMed Web of Science ®Google Scholar
• Shimatsu A, Hattori N. Macroprolactinemia: diagnostic, clinical, and pathogenic significance. Clin Dev Immunol 2012;167132. doi:10.1155/2012/167132
   PubMedGoogle Scholar
• Rodriguez-Espinosa J, Vanrell C, Sánchez Quesada JL, et al Prevalencia de macroprolactinemia en mujeres hiperprolactinémicas. Implicaciones clínicas. In: Gestión del Laboratorio Clínico Prevención de Riesgos. Madrid: Fundación Mapfre Medicina Ed.Editorial Mapfre SA; 2003:137–52
   Google Scholar
• Carlson HE, Markoff E, Lee DW. On the nature of serum prolactin in two patients with macroprolactinemia. Fertil Steril 1992;58:78–87
   PubMed Web of Science ®Google Scholar
• Fraser IS, Lun ZG, Zhou JP, et al Detailed assessment of big big prolactin in women with hyperprolactinemia and normal ovarian function. J Clin Endocrinol Metab 1989;69:585–92
   PubMed Web of Science ®Google Scholar
• Hattori N, Inagaki C. Anti-prolactin (PRL) autoantibodies cause asymptomatic hyperprolactinemia: bioassay and clearance studies of PRL-immunoglobulin G complex. J Clin Endocrinol Metab 1997;82:3107–10
   PubMed Web of Science ®Google Scholar
• Bjoro T, Morkrid L, Worgeland R, et al Frequency of hyperprolactinemia due to large molecular weight prolactin (150–170 kD PRL). Scand J Clin Lab Invest 1995;55:139–47
   PubMed Web of Science ®Google Scholar
• Kasum M, Oreskovic S, Zec I, et al Macroprolactinemia: new insights in hyperprolactinemia. Biochemia Medica: Časopis Hrvatskoga Društva Medicinskih Biokemičara/HDMB 2012;22:171–9
   Google Scholar
• Pinto LP, Evans LM, Davies JS, Scanlon MF. The TSH response to domperidone reflects the biological activity of prolactin in macroprolactinaemia and hyperprolactinaemia. Clin Endocrinol (Oxf) 2003;59:580–4
   PubMed Web of Science ®Google Scholar
• Espinoza JR, Trigos-Landa A, Bocanegra-Garcia V, et al Assessment of macroprolactin after poly-ethylene glycol precipitation in two commercial Immunoassay. Bioquimia 2006;31:140–5
   Google Scholar
• McCudden CR, Sharpless JL, Grenache DG. Comparison of multiple methods for identification of hyperprolactinemia in the presence of macroprolactin. Clin Chim Acta 2010;411:155–60
   PubMed Web of Science ®Google Scholar
• Hattori N, Ikekubo K, Ishihara T, et al Correlation of the antibody titers with serum prolactin levels and their clinical course in patients with anti-prolactin autoantibody. Eur J Endocrinol 1994;130:438–45
   PubMed Web of Science ®Google Scholar
• Hattori N, Adachi T, Ishihara T, Shimatsu A. The natural history of macroprolactinaemia. Eur J Endocrinol 2012;166:625–9
   PubMed Web of Science ®Google Scholar
• Elenkova A, Genov N, Abadzhieva Z, et al Macroprolactinemia in patients with prolactinomas: prevalence and clinical significance. Exp Clin Endocrinol Diabetes 2013;121:201–5
   PubMed Web of Science ®Google Scholar